DeCure for Severe X-linked mitochondrial encephalomyopathy
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for severe X-linked mitochondrial encephalomyopathy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSevere X-linked mitochondrial encephalomyopathy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for severe x-linked mitochondrial encephalomyopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
apoptosis inducing factor mitochondria associated 1 (AIFM1) — AIFM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet faddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KVI · 1.995 Å · ligand FLAVIN-ADENINE DINUCLEOTIDE (FAD). Experimental structure, not a prediction.
What the evidence adds up to
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by a deficiency of thymidine phosphorylase, leading to systemic accumulation of thymidine and 2'-deoxyuridine, progressive acquisition of secondary mitochondrial DNA mutations, and mtDNA depletion. The disease is characterised by gastrointestinal dysmotility, cachexia, peripheral neuropathy, ophthalmoplegia, ptosis, and leukoencephalopathy. It is progressively degenerative and leads to death at an average age of 37.6 years. Patients invariably encounter misdiagnoses, diagnostic delays, and non-specific clinical management. One case report describes MNGIE mimicking Guillain-Barre syndrome, and notes that multidisciplinary follow-up is important because the disease affects many systems and does not have a specific treatment.
No curative treatment is currently available for mitochondrial respiratory chain encephalomyopathies. A number of measures have been reported with theoretical potential to improve respiratory function, but these treatment strategies have variable scientific support, many reports being anecdotal. The molecular abnormality in MNGIE is metabolically and physically accessible to manipulation, which has invoked interest in developing therapeutic strategies, but this interest has not yet produced a proven therapy.
The abstracts provide no concrete survival or response rates for any drug in severe X-linked mitochondrial encephalomyopathy. No drug is named in any of the abstracts as having been tested in this disease. The 2000 review notes that the success of mtDNA study must move research into the next phase, but does not report any therapeutic results.
What is still missing is any completed trial of a specific drug for this condition, any validated patient stratification method, and the funding needed to move from theoretical accessibility of the metabolic defect to a tested intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Translational Genetics and Genomics · 2019 · 26 citations · open access
Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment
Abstractthe gene encoding for the enzyme thymidine phosphorylase. The resulting enzyme deficiency leads to a systemic accumulation of thymidine and 2'-deoxyuridine and ultimately mitochondrial failure due to a progressive acquisition of secondary mitochondrial DNA (mtDNA) mutations and mtDNA depletion. MNGIE is characterised by gastrointestinal dysmotility, cachexia, peripheral neuropathy, ophthalmoplegia, ptosis and leukoencephalopathy. The disease is progressively degenerative and leads to death at an average age of 37.6 years. Patients invariably encounter misdiagnoses, diagnostic delays, and non-specific clinical management. Despite its rarity, MNGIE has invoked much interest in the development of therapeutic strategies, mainly because it is one of the few mitochondrial disorders where the molecular abnormality is metabolically and physically accessible to manipulation. This review provides a resume of the current diagnosis and treatment approaches and aims to increase the clinical awareness of MNGIE and thereby facilitate early diagnosis and timely access to treatments, before the development of untreatable and irreversible organ damage.
The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective
AbstractThe mitochondrial respiratory chain encephalomyopathies represent an important group of multisystem disorders. No curative treatment is currently available. A number of measures have been reported to have a theoretical potential to improve respiratory function. These treatment strategies have variable scientific support, many reports being anecdotal. We critically review the various therapeutic measures employed and suggest future treatment directions.
AbstractMitochondrial encephalomyopathy is a disease based on multisystemic mitochondrial dysfunction. Pathologic, biochemical and molecular genetic approaches to the disease have revealed the complex features of the phenotype and its relationship to the genotype. Last decade's great success of the mtDNA study must move research of the disease into the next phase.
Journal of Clinical Images and Medical Case Reports · 2022 · 0 citations · open access
Mitochondrial neurogastrointestinal encephalomyopathy syndrome mimicking Guillain-Barre syndrome: A case report and literature review
AbstractMitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is rare autosomal recessive multisystem disorder characterized by severe gastrointestinal dysmotility and leads to cachexia, ptosis, external ophthalmoplegia, peripheral neuropathy, and leukoencephalopathy. Due to its complex clinical findings and non-specific symptoms, diagnosis may be delayed or patients may be misdiagnosed. Multidisciplinary follow-up and treatment of patients is important because it affects many systems and does not have a specific treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
